Abstract
Measurements of glucagon were performed in 31 patients with diabetic ketoacidosis before and during insulin therapy. Marked hyperglucagonemia was recorded in all patients. A significant correlation was found between the basal plasma levels of glucagon and those of glucose (r = 0.51, p <.05) and ketone bodies (r = 0.75, p <.01). The highest levels of glucagon were noted in the patients with non-ketotic hyperglycemia. Insulin therapy resulted in a significant suppression of glucagon levels which preceded any significant change in plasma glucose. Nevertheless, the correction of hyperglycemia occurred whilst absolute hyperglucagonemia still persisted. Although these results suggest that insulin has a direct inhibitory effect on glucagon secretion, they raise the question of the role of glucagon in the development of ketosis and hyperglycemia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Assan, R., Hautecouverture, G., Guillemant, S., Dauchy, F., Protin, P. and Dérot, M. (1969): Evolution de parametres hormonaux (glucagon, Cortisol, hormone somatotrope) et énergétiques (glucose, acides gras, glycerol libre) dans dix acido-cétoses diabétiques graves traitees. Path. Biol. 17, 1095–1105.
Barnes, A. J. and Bloom, S. R. (1976): Pancreatectomized man: a model for diabetes without glucagon. Lancet 1, 219–221.
Bergmeyer, H. V. (1973): Methods of Enzymatic Analysis, 2nd English Edition, Academic Press, New York.
Clark, M. G., Filsell, 0. H. and Jarrett, I. G. (1976): Gluconeogenesis in isolated intact lamb liver cells. Effects of glucagon and butyrate. Biochem. J. 156, 671–680.
Gerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H. and Forsham, P. H. (1975): Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. New Engl. J. Med. 292, 985–989.
Kraegen, E. W., Lazarus, L., Meier, H., Campbell, L. and Chia, Y. O. (1975): Carrier solutions for low level intravenous insulin infusion. Brit. Med. J. 3, 464–466.
Lazarus, L., Kraegen, E. W., Campbell, L., Casey, J. H., Zacharin, M. and Wienholt, J. (1976): Submitted for publication.
Lindsey, C. A., Faloona, G. R. and Unger, R. H. (1974): Plasma glucagon in non-ketotic hyperosmolar coma. JAMA 229, 1771–1773.
Lundbaek, K., Christensen, S. E., Hansen, A. P., Iversen, J., Ørskov, H., Seyer-Hansen, K., Alberti, K. G. M. M. and Whitefoot, R. (1976): Failure of somatostatin to correct manifest diabetic ketoacidosis. Lancet 1, 215–218.
Marco, J., Calli, C., Roman, D., Diaz-Fierros, M., Villanueva, M. L. and Valverde, I. (1973): Hyperglucagonism induced by glucocorticoid treatment in man. New Engl. J. Med. 288, 128–132.
Müller, W. A., Faloona, G. R. and Unger, R. H. (1973): Hyperglucagonemia in diabetic ketoacidosis. Am. J. Med. 54, 52–57.
Unger, R. H. (1976): Diabetes and the alpha cell. Diabetes 25, 136–151.
Wilcoxon, F. (1947): Probability tables for individual comparisons by ranking methods. Biometrics 3, 119–122.
Samols, E., Tyler, J. M. and Marks, V. (1972): Glucagon-insulin inter-relationships. In: Glucagon. Molecular Physiology, Clinical and Therapeutic Implications. P. J. Lefebvre and R. H. Unger, Eds. Pergamon Press, New York, pp. 151–173.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1977 Springer-Verlag New York Inc.
About this paper
Cite this paper
Lazarus, L., Kraegen, E.W., Meler, H., Zacharin, M., Campbell, L., Casey, J.H. (1977). Glucagon in Diabetic Coma. In: Foà, P.P., Bajaj, J.S., Foà, N.L. (eds) GLUCAGON: Its Role in Physiology and Clinical Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-6366-1_44
Download citation
DOI: https://doi.org/10.1007/978-1-4612-6366-1_44
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-6368-5
Online ISBN: 978-1-4612-6366-1
eBook Packages: Springer Book Archive